RT Journal Article
T1 Predictive performance and clinical application of COV50, a urinary proteomic biomarker in early COVID-19 infection: a prospective multicentre cohort study.
A1 Staessen, Jan A
A1 Wendt, Ralph
A1 Yu, Yu-Ling
A1 Kalbitz, Sven
A1 Thijs, Lutgarde
A1 Siwy, Justyna
A1 Raad, Julia
A1 Metzger, Jochen
A1 Neuhaus, Barbara
A1 Papkalla, Armin
A1 von der Leyen, Heiko
A1 Mebazaa, Alexandre
A1 Dudoignon, Emmanuel
A1 Spasovski, Goce
A1 Milenkova, Mimoza
A1 Canevska-Taneska, Aleksandra
A1 Salgueira Lazo, Mercedes
A1 Psichogiou, Mina
A1 Rajzer, Marek W
A1 Fuławka, Łukasz
A1 Dzitkowska-Zabielska, Magdalena
A1 Weiss, Guenter
A1 Feldt, Torsten
A1 Stegemann, Miriam
A1 Normark, Johan
A1 Zoufaly, Alexander
A1 Schmiedel, Stefan
A1 Seilmaier, Michael
A1 Rumpf, Benedikt
A1 Banasik, Mirosław
A1 Krajewska, Magdalena
A1 Catanese, Lorenzo
A1 Rupprecht, Harald D
A1 Czerwieńska, Beata
A1 Peters, Björn
A1 Nilsson, Åsa
A1 Rothfuss, Katja
A1 Lübbert, Christoph
A1 Mischak, Harald
A1 Beige, Joachim
A1 CRIT-CoV-U investigators, 
AB The SARS-CoV-2 pandemic is a worldwide challenge. The CRIT-CoV-U pilot study generated a urinary proteomic biomarker consisting of 50 peptides (COV50), which predicted death and disease progression from SARS-CoV-2. After the interim analysis presented for the German Government, here, we aimed to analyse the full dataset to consolidate the findings and propose potential clinical applications of this biomarker. CRIT-CoV-U was a prospective multicentre cohort study. In eight European countries (Austria, France, Germany, Greece, North Macedonia, Poland, Spain, and Sweden), 1012 adults with PCR-confirmed COVID-19 were followed up for death and progression along the 8-point WHO scale. Capillary electrophoresis coupled with mass spectrometry was used for urinary proteomic profiling. Statistical methods included logistic regression and receiver operating characteristic curve analysis with a comparison of the area under curve (AUC) between nested models. Hospitalisation costs were derived from the care facility corresponding with the Markov chain probability of reaching WHO scores ranging from 3 to 8 and flat-rate hospitalisation costs adjusted for the gross per capita domestic product of each country. From June 30 to Nov 19, 2020, 228 participants were recruited, and from April 30, 2020, to April 14, 2021, 784 participants were recruited, resulting in a total of 1012 participants. The entry WHO scores were 1-3 in 445 (44%) participants, 4-5 in 529 (52%) participants, and 6 in 38 (4%) participants; and of all participants, 119 died and 271 had disease progression. The odds ratio (OR) associated with COV50 in all 1012 participants for death was 2·44 (95% CI 2·05-2·92) unadjusted and 1·67 (1·34-2·07) when adjusted for sex, age, BMI, comorbidities, and baseline WHO score; and for disease progression, the OR was 1·79 (1·60-2·01) when unadjusted and 1·63 (1·41-1·91) when adjusted (p The urinary proteomic COV50 marker might be predictive of adverse COVID-19 outcomes. Even in people with mild-to-moderate PCR-confirmed infections (WHO scores 1-4), the 0·04 COV50 threshold justifies earlier drug treatment, thereby potentially reducing the number of days in hospital and associated costs. German Federal Ministry of Health.
YR 2022
FD 2022-08-31
LK http://hdl.handle.net/10668/22564
UL http://hdl.handle.net/10668/22564
LA en
DS RISalud
RD Apr 20, 2025